Company Filing History:
Years Active: 2006
Title: Michael Spruyt: Innovator in Target Specific Screening
Introduction
Michael Spruyt is an accomplished inventor based in Mahwah, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the area of target specific screening. His innovative work has led to the development of a patented method that enhances the identification of target binders.
Latest Patents
Michael Spruyt holds a patent for "Target specific screening and its use for identifying target binders." This invention relates to a modified phage display method for detecting and identifying targets and their corresponding binders. The method involves transforming host cells with two separate phages: one from a target or target library and another from a target-binder library. This process allows for the selection and elimination of non-paired targets and binders. Additionally, the invention encompasses antibodies that bind to complexes of targets and target binders, as well as nucleic acids encoding target and target binder peptides. The use of sequence information inherent in these targets and binders facilitates target validation through in silico approaches. Furthermore, the invention has applications in diagnostics and therapeutics, particularly in small molecule drug discovery and high throughput drug screening for cancers and similar disorders.
Career Highlights
Michael is currently associated with Antyra Inc., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biotechnology sector, contributing to innovative solutions that address complex medical challenges.
Collaborations
Michael collaborates with talented professionals in his field, including Renuka Pillutla and Renee Brissette. These partnerships enhance the scope and impact of his research, fostering an environment of innovation and discovery.
Conclusion
Michael Spruyt's contributions to target specific screening exemplify the intersection of innovation and biotechnology. His patented methods and ongoing work at Antyra Inc. highlight his commitment to advancing medical science and improving therapeutic outcomes.